Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients
NCT03034941 on ClinicalTrials.gov · last registry update 2017-01-27
A small phase 4 — 35 participants, against a typical 75. The sponsor logged completion for December 2016. Primary outcome, as filed: The main outcome was change in BMI. liraglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor type
- Other
- Enrollment
- 35
- Started
- 2014-04
- Primary completion
- 2016-12 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
The main outcome was change in BMI
Conditions studied
Obesity · PCOS
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.